Trial Profile
An open-label, randomized, 4-treatment, 3-period, crossover interaction study, evaluating the effect of esomeprazole 40 mg, omeprazole 80 mg or lansoprazole 60 mg on the pharmacodynamics and the pharmacokinetics of clopidogrel in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary) ; Lansoprazole (Primary) ; Omeprazole (Primary) ; Clopidogrel
- Indications Bleeding ulcer; Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 28 Mar 2014 Results published in the American Journal of Cardiovascular Drugs.
- 27 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 27 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.